Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Inks RNAi Product-Development, Manufacturing Deal with Roche

Premium

Tekmira Pharmaceuticals announced this week that it has signed a deal to help Roche advance its first two RNAi-based therapeutics into clinical testing. Both drugs will use Tekmira's proprietary stable nucleic acid-lipid particle, or SNALP, delivery technology.

Under the terms of the latest agreement, Roche will pay Tekmira up to $18.4 million to support the preclinical development of the two undisclosed drug candidates up until the filing of investigational new drug applications with US regulators. Tekmira may also receive up to $32 million in milestones, as well as royalties on future product sales.

Tekmira said it will develop and manufacture all drug product for preclinical testing, and will manufacture one batch of clinical product for phase I studies.

Additional terms were not disclosed.

"We believe Tekmira's SNALP is the leading lipid nanoparticle delivery technology and we are confident that Tekmira's research and manufacturing capabilities will help us to meet our product development objectives," Lou Renzetti, head of RNA therapeutics at Roche, said in a statement.

As previously reported by RNAi News, Roche expects to move its first RNAi-based drug into clinical testing sometime next year (see RNAi News, 2/14/2008).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more